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Common Transactivation Motif 9aaTAD recruits multiple general co-activators 
TAF9, MED15, CBP and p300 
 
 More than 2000 transcription factors are involved in the human gene regulation to provide 
cellular function and development. Transactivation domain, TAD, mediates the interaction of 
transcription factors with general transcriptional co-activators such as TAF9, MED15, CBP and p300. 
Recently reported NMR-data for interactions of these co-activators with transcription factors reveal 
tightly binding of KIX and TAZ domains to common 9aaTAD motif. Nine-amino-acid Trans-Activation 
Domain, 9aaTAD, defines a transactivation domain common to a large super-family of eukaryotic 
transcription factors represented in yeast by Gal4, Oaf1, Pdr1, Rtg3, Pho4, Gln3, Gcn4 and in mammals 
by p53, E2A, NFAT, NFkB, HSF1, NF-IL6, MLL, EBNA2, VP16. The 9aaTAD family was derived from 
the transcription factor Oaf1 and its close orthologs Gal4, Pdr1, Leu3, Tea1 and Cha4.  
 
 9aaTAD interactions with a general transcriptional co-activator TAF9/TAFII31 were reported (NMR 
and biochemical data: p53, VP16, HSF1, NF-IL6, NF- B and NFAT)1. 9aaTAD interactions with KIX domain 
of further general transcriptional co-activators MED15/Gal11 and CBP-p300 were recently reported (NMR data 
available for Oaf1, Pdr1 and p53)2-6. Oaf1-9aaTAD and Pdr1-9aaTAD3 upon binding to KIX domain of 
Med15/Gal11 (9 resp. 12 amino acid long peptides including 9aaTAD) reveal structural similarity, although 
none of the nine amino acids is conserved in both 9aaTADs (Table 1).  
 
 The interaction between TAF9 and p53-TAD1 was restricted by NMR to five amino acids (FSDLW) in 
the first annotated 9aaTAD of p53 (p53-9aaTAD1). The second annotated 9aaTAD (p53-9aaTAD2) and the 
pseudo-9aaTAD (p53-9aaTADpse) were located in p53-TAD2 (annotated results from 2007 available on 
www.expasy.ch/tools). Both p53-9aaTAD1 and p53-9aaTAD2 fulfil the criteria of 9aaTAD pattern, amino acid 
composition and hydrophobic profile (Fig.1).  
 
 Interestingly, CBP-p300 domains KIX, TAZ1, TAZ2 and IBiD are also able to bind p53-9aaTAD14,7 
(Table 2). The site of interaction between the KIX domain and both p53-TADs corresponds with the annotated 
9aaTADs and the TAF9 binding site (NMR data, eight out of nine annotated amino acids). Despite the 
unrecognizable sequence similarity (Table 2 and 3)4,7, both p53-TAD1 and p53-TAD2 share the same docking 
sites on the KIX domain, which may result from the presence of a common motif in the p53 transactivation 
domains, the 9aaTAD8. p53 and further well characterized 9aaTAD-transcription factors, which interact with 
CBP-p300 and other general co-activator GCN5 are listed in Table 3.  
 
 Structural similarities of TADs of p53, STAT1, CITED2 and HIF1a upon binding to TAZ domain were 
reported by PE Wright lab9. Bound TADs are wrapped around TAZ domain in the shared structural order of two 
helixes with linker (9aaTAD-loop-9aaTAD domain architecture are highlighted in Table 4). Coil-to-helix 
transition was observed in TAD2 peptide upon its binding to RPA (NMR data)10 giving disorder-to-order 
changes into helix-linker-helix conformation (9aaTADpse-loop-9aaTAD2). p53-TAD2 is wrapped around RPA 
in a very similar way to 9aaTADs of STAT1, CITED2 and HIF1a upon binding to TAZ domain9 (Table 4). Helix 
H2 (amino acids 47-55) unlike to helix H1 (amino acids 41-44) has the most extensive buried surface area and 
therefore appears to be the major determinant of the interaction. Helix H2 is located in the previously annotated 
p53-9aaTAD2 (amino acids 48-56) and helix H1 in the p53-9aaTADpse (amino acids 38-46) (Table 4). Both 
helixes are also involved in p53 binding to KIX domain and MDM24,7,11.  
 
 RPA is the major single-stranded DNA binding protein in the cell. In the recent report10, Bochkarev and 
Arrowsmith labs pointed out very impressively that p53-TAD2 imitates the single stranded DNA (peptide bound 
in the deep basic cleft corresponding to the nucleic acid-binding pocket of the OB fold of RPA). The analogy of 
9aaTAD to the DNA implies 9aaTAD in the function of a pseudo DNA-response element recognized by 
transcription factors of a higher order (9aaTAD mimics the DNA response element in order to recruit general 
transcription factors). DNA-mimicry for p53 was very recently reported for PC412. Both p53-9aaTAD and 
VP16-9aaTAD bind to PC4, TAF9, TFB1, MED15/Gal11, CBP-p300, GCN5-PCAF and other cofactors1,6,13,14. 
 
 Diverse transactivation domains15 were reported to interact with general transcriptional co-activators. 
None or extremely poor similarities were reported among the transactivation domains in general. Despite the 
enormous natural diversity, it was possible to generate a pattern and composition rules for 9aaTAD8. The 
establishment of 9aaTAD, its initial pattern and composition definition, identification and annotation (prediction 
correlated to experimental data) should streamline the investigations in gene regulation by transcription factors 
and the involvement of multiple transcriptional co-activators. The 9aaTAD prediction and online annotated 





































Oaf1_YEAST  D LFDY DFLF 
Pip2_YEAST  D FFDY DLLF 
Oaf2_CANGA  G VLDF EFLL 
Oaf1_ASHGO  D LLDY EFLF 
Oaf1_KLULA  D FFDY DFLL 
Oaf1_SACMI  D AFWE LLGE 
Oaf1_SACPA  T DLEE EYQF 
Oaf1_SACBA  T LFDV FIQR 
Annotated Gal4family-9aaTADs: 
Gal4_YEAST D DVYN YLFD 
Oaf1_YEAST  D LFDY DFLF 
Pdr1_YEAST E DLYS ILWS 







Interaction Experiment  p53-TAD Peptides 
TAF9 with p53-TAD1 NMR   SVEPPLSQ E TFSD LWKL 
KO mut. for interaction with TAF9  NMR               A    A 
KIX (CBP) with p53-TAD1 NMR        LSQ E TFSD LWKL LPE 
KIX (CBP) with p53-TAD2 NMR QAMDDLMLSP D DIEQ WFTE DPGPD 
KIX,TAZ1, TAZ2, IBiD (p300) NMR         SQ E TFSD LWKL LPEN 
KO mut. with KIX,TAZ1, TAZ2, IBiD 
GCN5: 
NMR                   QS 
 with p53-TAD2 CoIP    DDLMLSP D DIEQ WFTE 
DPGPDEAPRMPEAAPRV    Annotated p53-9aaTAD1:             E TFSD LWKL 
Annotated p53-9aaTAD2:             D DIEQ WFTE 




























p53 TADI -3,5 -0,7 2,8 -0,8 -3,5 3,8 -0,9 -3,9 3,8


























p53 TADII -3,5 -3,5 4,5 -3,5 -3,5 -0,9 2,8 -0,7 -3,5


























LW22QS -3,5 -0,7 2,8 -0,8 -3,5 -3,5 -0,8 -3,9 3,8


























WF53QS -3,5 -3,5 4,5 -3,5 -3,5 -3,5 -0,8 -0,7 -3,5
D D I E Q Q S T E
p53 TADI p53 TADII





































Annotated 9aaTADs interacting with multiple co-activators: 
CBP/p300, TAF9 or GCN5 
hp53 TAD1  E TFSD LWKL 
cp53 TAD1 E TFSE LWNL 
hp53 TAD2 D DIEQ WFTE 
cp53 TAD2 E SVVN WLDE 
yGal4* D DVYN YLFD 
  hNFAT1 D ELDF SILF 
pNFAT1 D EFDF SILF 
  HRX (ALL1/MLL) S DIMD FVLK 
AAC41377.1 S DIME FVLN 
MLL2,4 S EIVD FVLK 
  hSTAT1 TAD1 E EFDE VSRI 
hSTAT1 TAD2 V EFDS MMNT 
mSTAT1 TAD1 E EFDE MSRI 
mSTAT1 TAD2 P EFDS MMST 
hSTAT3 TAD1 R TLDS LMQF 
hSTAT3 TAD1 E SLTF DMEL 
  hTF65 TAD1 (NFkB) S IADM DFSA 
hTF65 TAD2 M DFSA LLSQ 
  HHV1F (VP16) Q MFTD ALGI 
HHV2H  Q MFTD AMGI 
  hEBNA2 E SWDY IFET 
hEBNA2/ W454F E SFEG IFET 
EBNA2 (RHESUS) E NWDD IFNV 
EBNA2 (PAPIO) N QWED IFNF 
  hTFE2 (E2A) D LLDF SMMF 
hITF2, hHTF4 D LLDF SAMF 
E12 (BRARE) D LLDF SIMF 
yRTG3 E TLDF SLVT 
  HSF1 S ALLD LFSP 
HSF2 D LLVD LFTS 
  hCEBPA (NF-IL6) 
 
E FLAD LFQH 
 hCEBPB 
 
D FLSD LFSD 
 mCEBPB 
 
D FLSD LFAD 
 hCEBPD 
 
E LFAD LFNS 
 hCEBPE 
 
Q LLSD LFAV 
 mCEBPE Q LLSD LFAM 
  hKLF2 S VLDF ILSM 
mKLF2 N VLDF ILSM 
hKLF4 D LLDL DFIL 
xKLF4 K FVDL DFIL 
  E1A_ADECT D YVLE LLEE 
E1A_ADECR E YVSQ LLED 
E1A_ADE41 D DMFQ GLLE 
E1A_ADE12 D DILE HLVD 




9aaTADs interacting with CBP-p300 and other co-activators are listed: p53-9aaTADs bind to TAF91 and CBP-
p300 (KIX, TAZ1, TAZ2 and IBiD domains)4,7 (Gal4-9aaTAD represent the 9aaTAD family)8, NFAT1 binds to 
TAF9 and CBP (TAZ-KIX and TAZ2 domains)16, MLL/ALL1 binds to TAF91 and CBP (KIX and TAZ2 
domain)2,9,17, STAT1 binds to TAZ1 and TAZ2 domain of CBP9, NFkB binds to TAF91 and CBP1,18, VP16 binds 
to TAF9, Gal11/MED15, CBP-p300 and GCN5-PCAF1,6,14, EBNA2 binds to CBP-p300 (N- and C-terminal 
domains) and PCAF6, E2A binds to SAGA complex (TAF9-GCN5) and CBP (KIX domain)19, HSF1 binds to 






































   9aaTAD  -     Loop     -   9aaTAD 
 E .F.. .F..                  E .F.. .F.. 
CITED2 E EVLM SLVI 
EM 
 G     LDRI    K ELPE LWLG 
CITED1  EVLM SLVV 
EL 
 G     LDRA    N ELPE LWLG 
CITED4  EALT SLEL 
EL 
 G     LHRV    R ELPE LFLG 
    HIF1a-1 S DLAC RLL  G QSMDES       GLPQLTSYD C EVNA PIQG  
HIF1a-2 C EVNA PIQ   G      SRNLLQ  G E ELLR ALDQ 
CHICK C EVNA PIQ   G      NRNLLQ  G E ELLR ALDQ 
HIF2 C EVNV PVL   G      SSTLLQ  G G DLLR ALDQ 
    
    STAT3    
HUMAN R TLDS LMQF  G NNGEGAEP SAG G     QF E SLTF DMEL 
XENLA G TFDS VMQF PG    EGSE  SGN G    NQF E TLTF DVDL 
TETFL R TLDS LMHN      EAEANP     G     HL D SLTL EMDV 
BRARE R TLDS LMHN      AAEANP     G     PL E SLTL DMEL 
    STAT1    
HUMAN E EFDE VSRI V  GS V EFDS MMNT 
MOUSE E EFDE MSRI V  G P EFDS MMST 
RAT   E EFDE MSKI V  G S EFDS MMSA 
    
p53-TAD1* E TFSD LWKL L  P  ENNVLSP          LPS  Q AMDD LMLS 
p53-TAD2* Q AMDD LMLS  P D DIEQ WFTE 
H1 and H2 Q AMDD LMLS  P D DIEQ WFTE 
    
 
Disorder-to-order changes giving helix-linker-helix conformation of 9aaTADs are listed (9aaTAD-loop-
9aaTAD). CITED2-, HIF1a- and STAT1-TAD share binding regions on TAZ domain of CBP (NMR data9,22, 
interacting regions are in bold and underlined). p53-TAD2 binds to RPA10 in a similar manner to the TADs of 
STAT1, CITED2 and HIF1a to TAZ. *Sequence similarity of STAT1- and p53-TAD was previously reported 
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